Hemagen Diagnostics, Inc. is a biotechnology company. The company is headquartered in Columbia, Maryland and currently employs 15 full-time employees. The firm is primarily focused on Veterinary Clinical Diagnostics. The company is also focused on VIRGO, its Human Clinical Diagnostic line of autoimmune and infectious disease products. The firm develops, manufactures and markets a range of test kits used to aid in the diagnosis of certain autoimmune and infectious diseases. The Company’s autoimmune product portfolio includes Hemagen DNA Kit, Hemagen Rheumatoid Factor Kit, VIRGO AMA IgG, VIRGO ANA/Hep-2 IgG, VIRGO Anti-nDNA IgG, VIRGO cANCA (PR-3) Kit, VIRGO dsDNA Kit, VIRGO ENA Screen 6 Kit, VIRGO ENA Screening, VIRGO ENA Series, VIRGO pANCA myeloperoxidase (MPO) Kit and VIRGO Rheumatoid Factor Kit. The company offers various products for infectious disease, which includes VIRGO C. trach IgG, VIRGO CMV IgG and VIRGO epstein-barr virus (EBV)- viral capsid antigen (VCA) IgG. Its products are used in laboratories, hospitals and blood banks around the world.
HMGN stock price ended at $0 on 星期一, after rising NaN%
On the latest trading day Jan 26, 2026, the stock price of HMGN rose by NaN%, climbing from $0.02 to $0.00. During the session, the stock saw a volatility of Infinity%, with prices oscillating between a daily low of $0.00 and a high of $0.02. Notably, trading volume dropped by 6.2K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 8.7K shares were traded, equating to a market value of approximately --.